Key facts
- It has raised $37.0M; the latest was Later Stage VC ($25.0M) in Sep 2025.
- Notable investors include Insight Partners (New York), UPMC Enterprises, Informed Ventures, Novant Health, University of Pittsburgh Medical Center — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Optain
- ·The full record, as it builds
Funding rounds
No funding rounds for Optain are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Optain
Developer of retinal imaging technology designed to offer noninvasive diagnosis of eye and systemic health conditions in real time. The company's technology empowers people with artificial intelligence and automation, using the eye as the gateway to detect and prevent diseases in their early stages, enabling medical doctors to accurately identify the early signs of various eye conditions.
- Sector
- Healthcare
- HQ
- Chadstone, Australia
- Founded
- 2019
- Website
- optainhealth.com/
- Ownership
- Privately Held (backing)
Optain doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Optain shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Optain in its N-PORT filings yet. We sweep new filings monthly.